Full video transcriptClick to expand
Auto-generated transcript of @dawson_weiss's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Long time. No see. Today I'm going to talk to you guys about the most efficient
- 0:06weight loss stack that you can take. That is going to be Red O'Truh Tide with
- 0:11Krogrilintide. These two together is really all you need and it saves you the
- 0:16most money. These two together have four mechanisms of action towards weight loss.
- 0:20You got Red O'Truh Tide's three mechanisms of action and then Krogrilintide
- 0:25hits a totally different receptor than what Red O'Truh Tide is already hitting.
- 0:28There's no other combo out there right now that can do this besides Red O'Truh
- 0:33Tide and Krogrilintide. Krogrilintide is most similar to semagluetide but it isn't
- 0:38a GLP1. It's an amylin agonist and has similar appetite suppressant qualities
- 0:43that semagluetide has without the side effects. As long as you keep the dosage
- 0:48low and slow. If you don't want to spend a lot of money on Red O'Truh Tide or you
- 0:52need a little bit more appetite suppressant help, Krogrilintide is your
- 0:56answer.
Retatrutide and cagrilintide stacked: what the science says
Quick answer
Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors currently in Phase 3 trials, while cagrilintide is an amylin analogue studied in Phase 2 and in combination with semaglutide by Novo Nordisk. Neither compound is FDA-approved, and the specific combination the creator recommends has no published clinical trial data supporting its safety or efficacy as a paired regimen. The dosing guidance offered in this video is not grounded in approved labeling and should not be followed without direct medical supervision.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Retatrutide and cagrilintide stacked: what the science says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Retatrutide and cagrilintide stacked: what the science says is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Retatrutide and cagrilintide stacked: what the science says" from Dawson Weiss. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors currently in Phase 3 trials, while cagrilintide is an amylin analogue studied in Phase 2 and in combination with semaglutide by Novo Nordisk.
The reason this review is not generic is the source wording and the canonical claim label "glp1 retatrutide cagrilintide is the most efficient fatloss stack." In this clip, the useful excerpt is: "Long time." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors currently in Phase 3 trials, while cagrilintide is an amylin analogue studied in Phase 2 and in combination with semaglutide by Novo Nordisk.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors currently in Phase 3 trials, while cagrilintide is an amylin analogue studied in Phase 2 and in combination with semaglutide by Novo Nordisk. Neither compound is FDA-approved, and the specific combination the creator recommends has no published clinical trial data supporting its safety or efficacy as a paired regimen. The dosing guidance offered in this video is not grounded in approved labeling and should not be followed without direct medical supervision.
- Neither retatrutide nor cagrilintide is FDA-approved as of mid-2025. Any available product is compounded or gray-market and is not equivalent to the investigational drugs used in clinical trials.
- Retatrutide showed up to 24.2% mean body weight reduction at 48 weeks in the REDEFINE 1 Phase 2 trial (Jastreboff et al., 2023, NEJM), but this was in a controlled clinical setting with medical monitoring.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Neither retatrutide nor cagrilintide is FDA-approved as of mid-2025. Any available product is compounded or gray-market and is not equivalent to the investigational drugs used in clinical trials.
- Retatrutide showed up to 24.2% mean body weight reduction at 48 weeks in the REDEFINE 1 Phase 2 trial (Jastreboff et al., 2023, NEJM), but this was in a controlled clinical setting with medical monitoring.
- Cagrilintide caused nausea and injection site reactions in 65-75% of participants at higher doses in Phase 2 trials (Enebo et al., 2021, The Lancet). The claim it has no side effects is not supported by that data.
- The retatrutide-plus-cagrilintide combination has no published clinical trial data. The combination being studied in trials pairs cagrilintide with semaglutide (CagriSema), not with retatrutide.
- Stacking two compounds with gastrointestinal side effect profiles without clinical oversight raises real risks including dehydration and electrolyte imbalance, particularly during upward dose titration.
- FDA-approved weight loss medications including semaglutide (Wegovy) and tirzepatide (Zepbound) have extensive published safety and efficacy data and are available through licensed prescribers.
- Self-directed dosing advice from social media, including the specific titration schedule in this video, is not a substitute for individualized medical supervision.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @dawson_weiss actually say?
The creator claimed that retatrutide combined with cagrilintide is "the most efficient weight loss stack" available, hitting four distinct receptors and saving money compared to alternatives. They described cagrilintide as an amylin agonist with appetite-suppressing effects "similar to semaglutide" but without the side effects, provided doses are kept low. They recommended starting cagrilintide at 0.25mg weekly and adjusting upward when progress stalls.
To be clear: this video is giving specific dosing guidance for two investigational peptides to a combined audience that likely includes people with no medical supervision. That context matters a lot for evaluating what follows.
Does the science back this up?
Partially, but with major caveats. The receptor pharmacology is broadly correct, but the claim that this combo is proven "most efficient" has no head-to-head trial support yet. Retatrutide is a GIP, GLP-1, and glucagon triple agonist currently in Phase 2 and Phase 3 trials. Cagrilintide is an amylin analogue being studied separately and in combination with semaglutide under the brand name CagriSema (Novo Nordisk).
The REDEFINE 1 trial (Jastreboff et al., 2023, NEJM) showed retatrutide produced up to 24.2% mean body weight reduction at 48 weeks, which is genuinely impressive. Cagrilintide's standalone data from Enebo et al. (2021, The Lancet) showed dose-dependent weight loss of up to 10.8% over 26 weeks. These are real numbers from real trials, but neither study tested the specific retatrutide-plus-cagrilintide combination the creator is recommending. The assertion that this pairing is definitively superior to all other combinations is not established by existing published evidence.
What did they get wrong (or right)?
They got the receptor classification right. Cagrilintide is not a GLP-1 agonist. It is an amylin receptor agonist, and distinguishing that from semaglutide's mechanism is accurate and worth crediting. The creator is correct that these two drugs hit different pathways.
What they got wrong is more significant. Saying cagrilintide has "similar appetite suppressant qualities that semaglutide has without the side effects" is misleading. Cagrilintide carries its own side effect profile, including nausea and injection site reactions (Enebo et al., 2021, The Lancet). No drug in this class is side-effect-free. More concerning, the creator is dispensing specific weekly dosing advice for two compounds that are not FDA-approved, not available through licensed pharmacy channels as approved drugs, and whose combination has not been studied in clinical trials at these doses. The claim that this stack "saves you the most money" frames experimental peptides as a consumer optimization problem, which glosses over real regulatory and safety questions.
What should you actually know?
Neither retatrutide nor cagrilintide is FDA-approved as of mid-2025. Retatrutide is in Phase 3 trials. Cagrilintide is being studied in the CagriSema combination with semaglutide by Novo Nordisk, not with retatrutide. Any product sold today as "retatrutide" or "cagrilintide" is a compounded or gray-market peptide, and compounded products are not equivalent to investigational drugs used in clinical trials.
The four-mechanism framing is pharmacologically plausible but untested as a combination. Stacking drugs with overlapping gastrointestinal side effect profiles without clinical oversight carries real risks, including severe nausea, dehydration, and electrolyte imbalances. The "low and slow" dosing advice might reduce acute side effects, but it does not substitute for medical monitoring.
If you are interested in GLP-1 class medications for weight management, FDA-approved options including semaglutide and tirzepatide exist, have robust safety data, and can be prescribed and monitored by a licensed provider.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dawson Weiss · TikTok creator
100.7K views on this video
Retatrutide + Cagrilintide is the most efficient fatloss stack there is. Low and slow, start cagri at 0.25mgs once weekly. Adjust up every 0.25mgs when stalling or wanting more appetite suppression. #fyp #fypシ #fatloss #weightloss #fitness
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about neither retatrutide nor cagrilintide?
Neither retatrutide nor cagrilintide is FDA-approved as of mid-2025. Any available product is compounded or gray-market and is not equivalent to the investigational drugs used in clinical trials.
What does the video say about retatrutide showed up to 24.2% mean body weight reduction at?
Retatrutide showed up to 24.2% mean body weight reduction at 48 weeks in the REDEFINE 1 Phase 2 trial (Jastreboff et al., 2023, NEJM), but this was in a controlled clinical setting with medical monitoring.
What does the video say about cagrilintide caused nausea?
Cagrilintide caused nausea and injection site reactions in 65-75% of participants at higher doses in Phase 2 trials (Enebo et al., 2021, The Lancet). The claim it has no side effects is not supported by that data.
What does the video say about the retatrutide-plus-cagrilintide combination has no published clinical trial data. the?
The retatrutide-plus-cagrilintide combination has no published clinical trial data. The combination being studied in trials pairs cagrilintide with semaglutide (CagriSema), not with retatrutide.
What does the video say about stacking two compounds with gastrointestinal side effect profiles without clinical?
Stacking two compounds with gastrointestinal side effect profiles without clinical oversight raises real risks including dehydration and electrolyte imbalance, particularly during upward dose titration.
What does the video say about fda-approved weight loss medications including semaglutide (wegovy)?
FDA-approved weight loss medications including semaglutide (Wegovy) and tirzepatide (Zepbound) have extensive published safety and efficacy data and are available through licensed prescribers.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dawson Weiss, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.